Literature DB >> 8542597

Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.

M Saleh1, S A Stacker, A F Wilks.   

Abstract

Tumor angiogenesis involves a combination of events including the production of inhibitors, proteases, and angiogenic factors that have a chemotactic and mitogenic effect on endothelial cells. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen that promotes angiogenesis in solid tumors, including brain tumors such as astrocytomas. As an approach to the development of new strategies for gene therapy of brain tumors, we have interrupted the VEGF/VEGF receptor paracrine pathway in an attempt to inhibit angiogenesis and thereby control tumor growth. Rat C6 glioma cells were transfected with a eukaryotic expression vector bearing an antisense-VEGF cDNA. Stable transfectants were observed to express reduced levels of VEGF in culture under hypoxic conditions. When implanted s.c. into nude (nu/nu) mice, growth of the antisense-VEGF cell lines was observed to be greatly inhibited compared to control cells, despite the fact that they have a faster division time in vitro. Analysis of these tumors revealed that they have fewer blood vessels and a higher degree of necrosis, which is a plausible explanation for the reduced tumor size. We believe antisense-VEGF can be successfully used to control tumor growth and may provide the basis for the development of antiangiogenic gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8542597

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  [Role of receptor tyrosine kinase in the angiogenesis].

Authors:  S Meyer; C Hafner; T Vogt
Journal:  Hautarzt       Date:  2002-09       Impact factor: 0.751

3.  Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.

Authors:  A Bogdanov; E Marecos; H C Cheng; L Chandrasekaran; H C Krutzsch; D D Roberts; R Weissleder
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 4.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

Review 5.  Gene therapy--its potential in surgery.

Authors:  Satoshi Gojo; Shin Yamamoto; Clive Patience; Christian LeGuern; David K C Cooper
Journal:  Ann R Coll Surg Engl       Date:  2002-09       Impact factor: 1.891

6.  Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells.

Authors:  Song Gu; Chang-Jian Liu; Tong Qiao; Xue-Mei Sun; Lei-Lei Chen; Le Zhang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

7.  Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.

Authors:  S Y Cheng; M Nagane; H S Huang; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

8.  Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma.

Authors:  D H Liu; X Y Zhang; D M Fan; Y X Huang; J S Zhang; W Q Huang; Y Q Zhang; Q S Huang; W Y Ma; Y B Chai; M Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

9.  Spatial expression of VEGF-A in human glioma.

Authors:  Mikael Johansson; Thomas Brännström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

10.  Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study.

Authors:  M A Konerding; E Fait; C Dimitropoulou; W Malkusch; C Ferri; R Giavazzi; D Coltrini; M Presta
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.